NanoViricides, Inc. (NYSE American: NNVC) a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s broad-spectrum antiviral drug, is progressing successfully.

In this article, we embark on an exploration of the risks and rewards associated with small-cap stocks.

In the world of technological advancement, few innovations hold as much promise as virtual reality (VR).

Present market dynamics and foreseeable headwinds cast a shadow over its short-term prospects, and we have little optimism for a significant turnaround in the upcoming quarters, especially given the fluctuating nature of wholesale demand.

Some of the best small cap options tend to lie within the technology, healthcare and consumer focused sectors due to their growth potential and transformative impact on industries.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company, deeply rooted in the mission of advancing therapies tailored for neuronal excitability disorders.

Applied UV Inc. (NASDAQ: AUVI), a key player in the realm of proprietary surface and air disinfection technology spanning multiple sectors, has recently announced an exciting financial update that highlights the company’s fantastic growth trajectory.